Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sigvotatug Vedotin + Pembrolizumab vs Pembrolizumab in 1L PD-L1 High NSCLC
NCT06758401Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jul 2025; status: recruiting.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06758401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758401.